This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas N. Chase, MD

Arch Neurol. 1972;27(4):354-356.

Abstract
Parachlorophenylalanine, a potent and specific depletor of brain serotonin, was administered to six patients with idiopathic parkinsonism. Although cerebrospinal fluid levels of 5-hydroxyindoleacetic acid, the principal metabolite of serotonin, were substantially reduced, no consistent change in cardinal parkinsonian signs was observed. These findings suggest that the alterations in central serotonin metabolism attending Parkinson's disease may reflect a secondary derangement which has no effect on the severity of the extrapyramidal signs characteristic of this disorder.

Author Affiliations
Bethesda, Md

From the Neurology Unit, National Institute of Mental Health, Bethesda, Md.

Footnotes
Accepted for publication May 4, 1972.

Reprint requests to Neurology Unit, National Institute of Mental Health, 9000 Rockville Pike, Bethesda, Md 20014 (Dr. Chase).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
Bibbiani et al.
Neurology 2001;57:1829-1834.
ABSTRACT | FULL TEXT  

Serotonin and 5-Hydroxyindoleacetic Acid in CSF: Difference in Parkinson's Disease and Dementia of the Alzheimer's Type
Volicer et al.
Arch Neurol 1985;42:127-129.
ABSTRACT  

Treatment With Tryptophan of Levodopa-Associated Psychiatric Disturbances
Beasley et al.
Arch Neurol 1980;37:155-156.
ABSTRACT  

Fenfluramine Hydrochloride Treatment of Parkinsonism
Beasley et al.
Arch Neurol 1977;34:255-256.
ABSTRACT